The growing worldwide incidence of diabetes requires more effective approaches for managing blood glucose levels. Insulin delivery systems have advanced significantly, with artificial intelligence (AI) playing a key role in improving their precision and adaptability. AI algorithms, particularly those based on reinforcement learning, allow for personalised insulin dosing by continuously adapting to an individual's responses. Despite these advancements, challenges such as data privacy, algorithm transparency, and accessibility still need to be addressed. Continued progress and validation in AI-driven insulin delivery systems promise to improve therapy outcomes further, offering people more effective and individualised management of their diabetes. This paper presents an overview of current strategies, key challenges, and future directions.

Senseonics has taken their Eversense implantable CGM before an FDA panel, and Bigfoot has announced they have closed their series B $55 million financing round. The FDA has approved Dexcom's G6 system, pushing shares in the company higher in early trading. And while they didn't announce anything recently, our friends at Tandem are feeling the love as shares continue to surge higher in anticipation of their new system, which has low glucose suspend. Simply put, when it comes to diabetes devices, CGM and insulin pumps, the joint is jumping. But before everyone breaks into an unstoppable happy dance, I'd advise they slow their roll.

A diabetes startup that uses artificial intelligence, Bigfoot Biomedical, has just announced that it scored a total of $55 million in Series B equity financing with new investments from Abbott and other existing funders. This funding is the culmination of earlier round funding that the company has been raising since late last year, including $37 million that it raised in December and an additional $18 million, which it announced this morning. The latest announcement now brings the company's total equity raised to $90 million. "We are excited to welcome Abbott to our list of investors," Jeffrey Brewer, president and CEO of Bigfoot Biomedical, said in a statement. "Abbott's inclusion in our financing speaks to our two companies' alignment of vision for changing the paradigm of care for people with insulin-requiring diabetes."